An investigation on behalf of current long term investors in IsoRay, Inc. (NYSEMKT:ISR) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NYSEMKT:ISR stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/29/2016 -- Certain directors of Richland, WA based IsoRay are under investigation over potential wrongdoing. The investigation was announced for investors in NYSEMKT:ISR shares was announced concerning potential breaches of fiduciary duties by certain IsoRay directors.
Investors who are current long term investors in IsoRay, Inc. (NYSEMKT:ISR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm for investors in NYSEMKT:ISR stocks follows a lawsuit filed against IsoRay, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSEMKT:ISR stocks, concerns whether certain IsoRay directors are liable in connection with the allegations made in that lawsuit. According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that the Defendants allegedly made false and/or misleading statements regarding IsoRay's Celsium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers and that when the true details entered the market, shares of IsoRay, Inc. (NYSEMKT:ISR) fell $1.10 per share or over 35% to close at $2.02 per share on May 21, 2015, damaging investors.
On May 20, 2015, IsoRay, Inc. announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.
Shares of IsoRay, Inc. (NYSEMKT:ISR) grew from $1.48 per share on May 19, 2015, to as high as $3.79 per share on May 21, 2015. However, on May 21, 2015, an article was published that said that "IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy" and "to make up for the inability to deliver revenue growth -- and prop up its stock price"
Shares of IsoRay, Inc. (NYSEMKT:ISR) closed on June 28, 2016 at $0.88 per share.
Those who purchased shares of IsoRay, Inc. have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com